Biodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company's BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Symbol: NASDAQ:ALBO
- CUSIP: N/A
- Web: www.albireopharma.com
Capitalization:- Market Cap: $164.91 million
- Outstanding Shares: 6,292,000
Average Prices:- 50 Day Moving Avg: $21.33
- 200 Day Moving Avg: $21.55
- 52 Week Range: $9.90 - $37.69
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.58
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $11.24 million
- Price / Sales: 14.67
- Book Value: $4.96 per share
- Price / Book: 5.28
Profitability:Debt:- Current Ratio: 2.35%
- Quick Ratio: 2.35%
Misc:- Average Volume: 32,946 shs.
- Beta: 1.43
- Short Ratio: 2.01
Frequently Asked Questions for Biodel (NASDAQ:ALBO)
What is Biodel's stock symbol?
Biodel trades on the NASDAQ under the ticker symbol "ALBO."
How were Biodel's earnings last quarter?
Biodel Inc. (NASDAQ:ALBO) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($1.06) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.04. View Biodel's Earnings History.
Where is Biodel's stock going? Where will Biodel's stock price be in 2017?
4 analysts have issued 12-month target prices for Biodel's stock. Their predictions range from $35.00 to $35.00. On average, they anticipate Biodel's stock price to reach $35.00 in the next year. View Analyst Ratings for Biodel.
Who are some of Biodel's key competitors?
Some companies that are related to Biodel include RTI Surgical (RTIX), Selecta Biosciences (SELB), Tetraphase Pharmaceuticals (TTPH), Corbus Pharmaceuticals Holdings (CRBP), Rigel Pharmaceuticals (RIGL), Edge Therapeutics (EDGE), Concert Pharmaceuticals (CNCE), Merus N.V. (MRUS), Miragen Therapeutics (MGEN), Syndax Pharmaceuticals (SNDX), Pacific Biosciences of California (PACB), Aratana Therapeutics (PETX), ViewRay (VRAY), Celldex Therapeutics (CLDX), Senseonics Holdings (SENS), Minerva Neurosciences (NERV), Curis (CRIS) and GlycoMimetics (GLYC).
How do I buy Biodel stock?
Shares of Biodel can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biodel's stock price today?
One share of Biodel stock can currently be purchased for approximately $26.21.
MarketBeat Community Rating for Biodel (NASDAQ ALBO)MarketBeat's community ratings are surveys of what our community members think about Biodel and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Biodel (NASDAQ:ALBO)Earnings History by Quarter for Biodel (NASDAQ ALBO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2017 | Q2 2017 | ($1.11) | ($1.06) | | | View | N/A |  |
| 8/11/2016 | Q216 | | ($0.05) | | | View | N/A | |
| 5/9/2016 | Q2 | ($0.04) | ($0.09) | | | View | N/A | |
| 2/16/2016 | Q1 | ($0.08) | ($0.05) | | | View | N/A | |
| 12/17/2015 | Q315 | ($0.11) | ($0.05) | | | View | Listen | |
| 8/13/2015 | Q3 | ($0.10) | ($0.12) | | | View | Listen | |
| 5/6/2015 | Q215 | ($0.23) | ($0.27) | | | View | N/A | |
| 2/12/2015 | Q115 | ($0.18) | ($0.20) | | | View | N/A | |
| 12/17/2014 | Q414 | ($0.27) | ($0.16) | | | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.26) | ($0.15) | | | View | N/A | |
| 5/13/2014 | Q114 | ($0.26) | ($0.29) | | | View | N/A | |
| 2/6/2014 | Q4 | ($0.19) | ($0.20) | | | View | N/A | |
| 12/18/2013 | Q4 | ($0.30) | ($0.04) | | | View | Listen | |
| 8/12/2013 | Q3 2013 | ($0.37) | ($0.66) | | | View | N/A | |
| 5/8/2013 | Q2 2013 | ($0.43) | ($0.37) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Biodel (NASDAQ:ALBO)2017 EPS Consensus Estimate: ($3.24)
2018 EPS Consensus Estimate: ($4.03)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.91) | ($0.91) | ($0.91) |
| Q2 2017 | 1 | ($0.87) | ($0.87) | ($0.87) |
| Q3 2017 | 1 | ($0.52) | ($0.52) | ($0.52) |
| Q4 2017 | 1 | ($0.94) | ($0.94) | ($0.94) |
| Q1 2018 | 1 | ($1.01) | ($1.01) | ($1.01) |
| Q2 2018 | 1 | ($1.01) | ($1.01) | ($1.01) |
| Q3 2018 | 1 | ($1.01) | ($1.01) | ($1.01) |
| Q4 2018 | 1 | ($1.00) | ($1.00) | ($1.00) |
(Data provided by Zacks Investment Research)
Dividend History for Biodel (NASDAQ:ALBO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biodel (NASDAQ:ALBO)Insider Ownership Percentage: 22.30%
Institutional Ownership Percentage: 12.35%
Insider Trades by Quarter for Biodel (NASDAQ:ALBO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/20/2013 | Brian Jg Pereira | Director | Sell | 4,734 | $2.26 | $10,698.84 | |
(Data available from 1/1/2013 forward)
Headline Trends for Biodel (NASDAQ:ALBO)
Latest Headlines for Biodel (NASDAQ:ALBO)
| Source: |
|
| Date | Headline |
|---|
 | Endo International PLC (ENDP) and Biodel (NASDAQ:ALBO) Financial Review
www.americanbankingnews.com - July 16 at 2:11 PM |
| Biodel Inc. (ALBO) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:38 PM |
| Comparing Biodel (NASDAQ:ALBO) & Endo International PLC (ENDP)
www.americanbankingnews.com - July 7 at 8:28 PM |
| Zacks: Biodel Inc. (ALBO) Given $49.00 Average Price Target by Brokerages
www.americanbankingnews.com - July 6 at 10:37 PM |
| Biodel (ALBO) & Endo International PLC (ENDP) Financial Comparison
www.americanbankingnews.com - July 6 at 12:32 AM |
| Research Analysts Set Expectations for Biodel Inc.'s FY2017 Earnings (NASDAQ:ALBO)
www.americanbankingnews.com - July 3 at 8:34 AM |
| Biodel Inc. (NASDAQ:ALBO) Receives New Coverage from Analysts at Wedbush
www.americanbankingnews.com - July 1 at 12:02 PM |
| Brokerages Anticipate Biodel Inc. (ALBO) Will Announce Earnings of -$0.87 Per Share
www.americanbankingnews.com - June 29 at 6:26 PM |
| Analyzing Biodel (ALBO) & Endo International PLC (ENDP)
www.americanbankingnews.com - June 27 at 12:40 AM |
| Analysts Anticipate Biodel Inc. (ALBO) to Post ($0.87) EPS
www.americanbankingnews.com - June 21 at 6:32 PM |
| Analysts Expect Albireo Pharma, Inc. (ALBO) Will Post Earnings of -$0.87 Per Share
www.americanbankingnews.com - June 5 at 4:06 PM |
| Albireo Pharma, Inc. (ALBO) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - June 2 at 7:30 PM |
 | Company Spotlight: Albireo Pharma - Nasdaq.com - Nasdaq
www.nasdaq.com - June 2 at 4:33 PM |
| Q2 2017 EPS Estimates for Albireo Pharma, Inc. (ALBO) Raised by William Blair
www.americanbankingnews.com - June 2 at 7:18 AM |
 | Company Spotlight: Albireo Pharma
www.rttnews.com - June 2 at 1:46 AM |
| ALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD - Nasdaq
www.nasdaq.com - May 31 at 3:26 PM |
 | Albireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com - May 31 at 11:06 AM |
| Zacks: Albireo Pharma, Inc. (ALBO) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - May 31 at 8:34 AM |
| Albireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters' Option to Purchase ... - GlobeNewswire (press release)
globenewswire.com - May 30 at 8:36 PM |
 | Albireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - May 30 at 8:36 PM |
| BUZZ-U.S. STOCKS ON THE MOVE-Micron Technology, Atwood Oceanics, Xactly, Protagonist Therapeutics ... - Nasdaq
www.nasdaq.com - May 30 at 3:35 PM |
 | Albireo Pharma (ALBO) Prices 2.2M Common Stock Offering at $20.50/Share - StreetInsider.com
www.streetinsider.com - May 25 at 1:36 AM |
| Albireo Pharma (ALBO) Prices 2.2M Common Stock Offering at $20.50/Share
www.streetinsider.com - May 24 at 3:26 PM |
| Albireo Prices $45.1 Million Public Offering of Common Stock
finance.yahoo.com - May 24 at 3:26 PM |
| Albireo Pharma (ALBO) Commences Offering of Common Stock - StreetInsider.com
www.streetinsider.com - May 24 at 7:23 AM |
| Albireo Announces Proposed Public Offering of Common Stock
finance.yahoo.com - May 24 at 7:23 AM |
| Albireo Pharma, Inc. (ALBO) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 23 at 7:28 PM |
| Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC
finance.yahoo.com - May 18 at 12:18 PM |
| Albireo Pharma (ALBO) Reports Two New U.S. Patents Allowed for A4250 with Term into 2031
www.streetinsider.com - May 16 at 8:33 PM |
| Albireo Pharma, Inc. (ALBO) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 16 at 8:18 PM |
| Albireo Pharma (ALBO) Reports Two New U.S. Patents Allowed for ... - StreetInsider.com
www.streetinsider.com - May 16 at 3:31 PM |
| Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031
finance.yahoo.com - May 16 at 3:31 PM |
| Albireo Pharma, Inc. (ALBO) Announces Earnings Results
www.americanbankingnews.com - May 11 at 5:10 PM |
| Albireo Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 11 at 1:39 AM |
| Albireo Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 8:38 PM |
| Albireo Pharma, Inc. (ALBO) Expected to Announce Earnings of -$0.91 Per Share
www.americanbankingnews.com - May 10 at 8:16 AM |
| Brokerages Set $40.00 Target Price for Albireo Pharma, Inc. (ALBO)
www.americanbankingnews.com - May 5 at 10:42 AM |
| Albireo Announces Elobixibat Data from Japan to be Presented at DDW 2017
finance.yahoo.com - April 27 at 3:49 PM |
| Albireo Pharma (ALBO) to Present Pediatric Data for A4250 at The International Liver Congress - StreetInsider.com
www.streetinsider.com - April 24 at 3:28 PM |
| Promising Pediatric Data for Albireo's A4250 to be Presented at The ... - GlobeNewswire (press release)
globenewswire.com - April 22 at 3:23 PM |
| Promising Pediatric Data for Albireo’s A4250 to be Presented at The International Liver Congress™ 2017
finance.yahoo.com - April 22 at 10:43 AM |
| Analysts Anticipate Albireo Pharma, Inc. (ALBO) to Post ($0.91) EPS
www.americanbankingnews.com - April 20 at 3:20 PM |
| Zacks: Analysts Expect Albireo Pharma, Inc. (ALBO) Will Announce Earnings of -$0.91 Per Share
www.americanbankingnews.com - April 19 at 7:33 AM |
| Albireo Pharma, Inc. (ALBO) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 10 at 9:03 PM |
| Albireo to Host KOL Meeting on Rare Pediatric Liver Diseases on April 12
finance.yahoo.com - April 10 at 3:28 PM |
 | Albireo Pharma (ALBO) Presents At 16th Annual Needham Healthcare Conference - Slideshow
seekingalpha.com - April 7 at 8:28 PM |
| Albireo Pharma (ALBO) Says A4250 Data Selected for Late Breaker Presentation as ILC - StreetInsider.com
www.streetinsider.com - April 7 at 7:49 AM |
| EASL Selects Albireo’s A4250 Data for Late Breaker Presentation
finance.yahoo.com - April 7 at 7:49 AM |
| Albireo Pharma, Inc. (ALBO) Given $40.00 Average Price Target by Brokerages
www.americanbankingnews.com - April 5 at 3:23 PM |
| Short Interest in Albireo Pharma, Inc. (ALBO) Declines By 7.4%
www.americanbankingnews.com - April 5 at 11:46 AM |
Biodel (ALBO) Chart for Sunday, July, 23, 2017
